Masimo Corp. Reports Director Departure, New CMO

Ticker: MASI · Form: 8-K · Filed: Nov 18, 2024 · CIK: 937556

Masimo CORP 8-K Filing Summary
FieldDetail
CompanyMasimo CORP (MASI)
Form Type8-K
Filed DateNov 18, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.001, $1,042,000, $621,250
Sentimentneutral

Sentiment: neutral

Topics: leadership-change, executive-appointment, compensation

Related Tickers: MASI

TL;DR

Masimo's board sees a change with Bruce out, O'Reilly in as CMO. Executive pay details also disclosed.

AI Summary

Masimo Corp. announced on November 13, 2024, the departure of Director David Bruce and the appointment of Dr. Michael O'Reilly as Chief Medical Officer. The company also disclosed compensatory arrangements for certain officers. This filing follows a period of significant corporate activity for Masimo.

Why It Matters

Changes in key leadership roles and executive compensation can signal shifts in company strategy or performance, impacting investor confidence and future operations.

Risk Assessment

Risk Level: medium — Leadership changes and executive compensation disclosures can introduce uncertainty and affect investor sentiment.

Key Players & Entities

FAQ

Who has departed from Masimo Corp.'s board of directors?

David Bruce has departed from Masimo Corp.'s board of directors as of November 13, 2024.

Who has been appointed as the new Chief Medical Officer at Masimo Corp.?

Dr. Michael O'Reilly has been appointed as the new Chief Medical Officer at Masimo Corp.

What is the reporting date for this Form 8-K filing?

The earliest event reported in this Form 8-K filing is dated November 13, 2024.

What are the main items disclosed in this 8-K filing?

This filing discloses the departure of a director, the appointment of a new Chief Medical Officer, and compensatory arrangements of certain officers.

What is Masimo Corp.'s principal executive office address?

Masimo Corp.'s principal executive office is located at 52 Discovery, Irvine, CA 92618.

Filing Stats: 792 words · 3 min read · ~3 pages · Grade level 12.7 · Accepted 2024-11-18 09:01:41

Key Financial Figures

Filing Documents

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) The following items are filed as exhibits to the Current Report on Form 8-K. Exhibit No. Description 10.1 Employment Agreement, by and between Masimo Corporation and Michelle Brennan, dated November 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Masimo Corporation has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. MASIMO CORPORATION Date: November 18, 2024 By: /s/ M ICAH Y OUNG Micah Young Executive Vice President & Chief Financial Officer (Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing